Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Oragenics, Inc. today announced that the company will host a webinar panel on Neurotrauma Medicine Monday, May 20, 2024, at 12:00 PM ET.

Praxis Precision Medicines, Inc. announced that on June 3, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 300 shares of its common stock and restricted stock unit awards covering an aggregate of 225 shares of its common stock to one new non-executive employee under the Praxis Precision Medicines, Inc. 2024 Inducement Plan.

Waters Corporation announced a new accessory for its TA Instruments Discovery Hybrid Rheometers designed to enable simultaneous electrical impedance and rheological measurements, a critical capability for scientists working on new battery formulations.

Praxis Precision Medicines, Inc. announced that on May 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,800 shares of its common stock and restricted stock unit awards covering an aggregate of 5,851 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc.

Rheos Medicines today announced that it has appointed Soumya Raychaudhuri, M.D., Ph.D., and Cornelia Weyand, M.D., to its Scientific Advisory Board (SAB).

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock.